Delivery Order SPE2DB20D1004-SPE2DB24FF1C3
- Not listed
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Glyburide-Metformin 5-500 mg medication. The contract has a ceiling value of $23,674.31 and a period of performance through April 28, 2023. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., also...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,968.16, is for the delivery of Glipizide-Metformin 5-500 mg tablets over a period ending on April 15, 2024. It is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora,...
- This federal contract award is for the delivery of Glyburide 5 mg tablets in quantities of 1,000 to the Defense Logistics Agency (DLA). The contract has a ceiling value of $2,245.80 and was awarded to Amerisourcebergen Drug Corp, the Corporate Office division of Amerisourcebergen Corporation, a major pharmaceutical distribution company. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December...
- This federal contract award is for the delivery of Metformin HCL ER 500 mg tablets in 1,000-count bottles to the Defense Logistics Agency (DLA). The $1,203.12 firm-fixed-price delivery order was issued under an existing Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 held by Cencora, Inc., doing business as Amerisourcebergen, with the DLA Troop Support Medical. This IDC serves as the primary vehicle for Amerisourcebergen to provide a wide range of pharmaceutical products and...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,141.51, is for the delivery of Glipizide-Metformin 2.5-250 mg tablets, a medication used to treat diabetes. The contract is a Firm Fixed Price Delivery Order with a performance period ending on March 6, 2025. The contract does not have a set-aside designation, indicating open competition....
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,113.38 Firm Fixed Price Delivery Order contract is for the supply of Glipizide-Metformin 2.5-500 mg tablets, a medication used to treat diabetes. The contract has a period of performance through July 1, 2024. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The order is for 4,562,626,703 units of the drug Glyburide-Metformin 2.5-500 mg, with a potential value of $1,452.32. The order has an anticipated completion date of October 30, 2023. Amerisourcebergen Drug Corp, through its Corporate Office division, has...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,531.50 firm fixed-price delivery order is for the supply of Metformin HCL 1,000 mg tablets, a common medication for diabetes management. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $341,640.00 firm-fixed-price delivery order is for the supply of 4532067832 units of Glyburide 5mg tablets, a medication used to treat diabetes. This order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, which serves as a primary...
- This federal contract award to Amerisourcebergen Drug Corporation, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of Metformin HCl 1,000 mg tablets. The firm-fixed-price delivery order, valued at $1,535.40, has a period of performance through November 2024. The contract is not designated as a set-aside. Amerisourcebergen holds a broader $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB24FF1C3Delivery Order
This federal contract award is for the delivery of Glyburide-Metformin 5-500 mg, 100 count, to the Defense Logistics Agency (DLA). The contract, valued at $1,053.52, was awarded to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. This is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that has established itself as a key vendor for federal healthcare programs, particularly within military and veterans' healthcare systems. The company holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This specific delivery order contract for Glyburide-Metformin is likely part of the broader IDC, enabling the efficient procurement of essential medications for federal medical facilities and beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 12/26/23 |